Viridax™

1. Abdul-Hassan, H. S., E. El-Tahan, B. Massoud, and R. Gomaa. 1990. Bacteriophage therapy of Pseudomonas burn wound sepsis. Ann. Medit. Burn Club 3:262-264.

2. Adamia, R. S., E. A. Matitashvili, L. I. Kvachadze, V. I. Korinteli, D. A. Matoyan, M. I. Kutateladze, and T. G. Chanishvili. 1990. The virulent bacteriophage IRA of Salmonella typhimurium: cloning of phage genes which are potentially lethal for the host cell. J. Basic Microbiol. 10:707-716.

3. Alisky, J., K. Iczkowski, A. Rapoport, and N. Troitsky. 1998. Bacteriophages show promise as antimicrobial agents. J. Infect. 36:5-15.

4. Anpilov, L. I., and A. A. Prokudin. 1984. Preventive effectiveness of dried polyvalent Shigella bacteriophage in organized collective groups. Voenno-Med. Zh. 5:39-40.

5. Babalova, E. G., K. T. Katsitadze, L. A. Sakvarelidze, N. S. Imnaishvili, T. G. Sharashidze, V. A. Badashvili, G. P. Kiknadze, A. N. Meipariani, N. D. Gendzekhadze, E. V. Machavariani, K. L. Gogoberidze, E. I. Gozalov, and N. G. Dekanosidze. 1968. Preventive value of dried dysentery bacteriophage. Zh. Mikrobiol. Epidemiol. Immunobiol. 2:143-145.

6. Barrow, P. A., and J. S. Soothill. 1997. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol. 7:268-271.

7. Bogovazova, G. G., N. N. Voroshilova, and V. M. Bondarenko. 1991. The efficacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection. Zh. Mikrobiol. Epidemiol. Immunobiol. 4:5-8.

8. Bordet, J., and M. Ciuca. 1921. Remarques sur l'historique de recherches concernant la lyse microbienne transmissible. Compt. Rend. Soc. Biol. 84:745-747.

9. Bruynoghe, R., and J. Maisin. 1921. Essais de thérapeutique au moyen du bacteriophage. C. R. Soc. Biol. 85:1120-1121.

10. Carlton, R. M. 1999. Phage therapy: past history and future prospects. Arch. Immunol. Ther. Exp. 5:267-274.

11. Cerveny, K. E., DePaola, A., Duckworth, D. H., Gulig, P. A. (2002). Phage Therapy of Local and Systemic Disease Caused by Vibrio vulnificus in Iron-Dextran-Treated Mice. Infect. Immun. 70: 6251-6262.

12. Chernomordik, A. B. 1989. Bacteriophages and their therapeutic-prophylactic use. Med. Sestra 6:44-47.

13. Chibani-Chennoufi, S., Sidoti, J., Bruttin, A., Dillmann, M.-L., Kutter, E., Qadri, F., Sarker, S. A., Brussow, H. (2004). Isolation of Escherichia coli Bacteriophages from the Stool of Pediatric Diarrhea Patients in Bangladesh. J. Bacteriol. 186: 8287-8294.

14. Chibani-Chennoufi, S., Bruttin, A., Dillmann, M.-L., Brussow, H. (2004). Phage-Host Interaction: an Ecological Perspective. J. Bacteriol. 186: 3677-3686.

15. Cislo, M., M. Dabrowski, B. Weber-Dabrowska, and A. Woyton. 1987. Bacteriophage treatment of suppurative skin infections. Arch. Immunol. Ther. Exp. 2:175-183.

16. d'Herelle, F. 1917. Sur un microbe invisible antagoniste des bacilles dysentériques. C. R. Acad. Sci. (Paris) 165:373-375.

17. d'Herelle, F. 1930. The bacteriophage and its clinical applications. Charles C Thomas, Springfield, Ill.

18. Eaton, M. D., and S. Bayne-Jones. 1934. Bacteriophage therapy. Review of the principles and results of the use of bacteriophage in the treatment of infections. JAMA 23:1769-1939.

19. Goode, D., Allen, V. M., Barrow, P. A. (2003). Reduction of Experimental Salmonella and Campylobacter Contamination of Chicken Skin by Application of Lytic Bacteriophages. Appl. Environ. Microbiol. 69: 5032-5036.

20. Hagens, S., Habel, A., von Ahsen, U., von Gabain, A., Blasi, U. (2004). Therapy of Experimental Pseudomonas Infections with a Nonreplicating Genetically Modified Phage. Antimicrob. Agents Chemother. 48: 3817-3822

21. Hankin, E. H. 1896. L'action bactericide des eaux de la Jumna et du Gange sur le vibrion du cholera. Ann. Inst. Pasteur 10:511.

22. Ioseliani, G. D., G. D. Meladze, N. S. Chkhetiia, M. G. Mebuke, and N. I. Kiknadze. 1980. Use of bacteriophage and antibiotics for prevention of acute postoperative empyema in chronic suppurative lung diseases. Grudn. Khir. 6:63-67.

23. Kaczkowski, H., B. Weber-Dabrowska, M. Dabrowski, Z. Zdrojewicz, and F. Cwioro. 1990. Use of bacteriophages in the treatment of chronic bacterial diseases. Wiad. Lek. 43:136-141.

24. Kiknadze, G. P., M. M. Gadua, E. V. Tsereteli, L. S. Mchedlidze, and T. V. Birkadze. 1986. Efficiency of preventive treatment by phage preparations of children's hospital salmonellosis, p. 41-44. In G. P. Kiknadze (ed.), Intestinal infections. Sovetskaya Meditsina, Tbilisi, Georgia.

25. Kochetkova, V. A., A. S. Mamontov, R. L. Moskovtseva, E. I. Erastova, E. I. Trofimov, M. I. Popov, and S. K. Dzhubalieva. 1989. Phagotherapy of postoperative suppurative-inflammatory complications in patients with neoplasms. Sov. Med. 6:23-26.

26. Krueger, A. P., and E. J. Scribner. 1941. Bacteriophage therapy. II. The bacteriophage: its nature and its therapeutic use. JAMA 19:2160-2277.

27. Kucharewicz-Krukowska, A., and S. Slopek. 1987. Immunogenic effect of bacteriophage in patients subjected to phage therapy. Arch. Immunol. Ther. Exp. 5:553-561.

28. Kwarcinski, W., B. Lazarkiewicz, B. Weber-Dabrowska, J. Rudnicki, K. Kaminski, and M. Sciebura. 1994. Bacteriophage therapy in the treatment of recurrent subphrenic and subhepatic abscess with jejunal fistula after stomach resection. Pol. Tyg. Lek. 49:535.

29. Lang, G., P. Kehr, H. Mathevon, J. M. Clavert, P. Sejourne, and J. Pointu. 1979. Bacteriophage therapy of septic complications of orthopaedic surgery. Rev. Chir. Orthop. Reparatrice Appar. Mot. 1:33-37.

30. Langley, R., Kenna, D. T., Vandamme, P., Ure, R., Govan, J. R. W. (2003). Lysogeny and bacteriophage host range within the Burkholderia cepacia complex. J Med Microbiol 52: 483-490.

31. Leverentz, B., Conway, W. S., Camp, M. J., Janisiewicz, W. J., Abuladze, T., Yang, M., Saftner, R., Sulakvelidze, A. (2003). Biocontrol of Listeria monocytogenes on Fresh-Cut Produce by Treatment with Lytic Bacteriophages and a Bacteriocin. Appl. Environ. Microbiol. 69: 4519-4526.

32. Levin, B., and J. J. Bull. 1996. Phage therapy revisited: the population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am. Naturalist 147:881-898.

33. Litvinova, A. M., V. M. Chtetsova, and I. G. Kavtreva. 1978. Evaluation of efficacy of the use of E. coli-Proteus bacteriophage in intestinal dysbacteriosis in premature infants. Vopr. Okhr. Materin. Det. 9:42-44.

34. Meladze, G. D., M. G. Mebuke, N. S. Chkhetia, N. I. Kiknadze, G. G. Koguashvili, I. I. Timoshuk, N. G. Larionova, and G. K. Vasadze. 1982. The efficacy of staphylococcal bacteriophage in treatment of purulent diseases of lungs and pleura. Grudn. Khir. 1:53-56.

35. Merril, C. R., B. Biswas, R. Carlton, N. C. Jensen, G. J. Creed, S. Zullo, and S. Adhya. 1996. Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. USA 8:3188-3192

36. Mizoguchi, K., Morita, M., Fischer, C. R., Yoichi, M., Tanji, Y., Unno, H. (2003). Coevolution of Bacteriophage PP01 and Escherichia coli O157:H7 in Continuous Culture. Appl. Environ. Microbiol. 69: 170-176.

37. O'Flaherty, S., Ross, R. P., Meaney, W., Fitzgerald, G. F., Elbreki, M. F., Coffey, A. (2005). Potential of the Polyvalent Anti-Staphylococcus Bacteriophage K for Control of Antibiotic-Resistant Staphylococci from Hospitals. Appl. Environ. Microbiol. 71: 1836-1842.

39. O'Flynn, G., Ross, R. P., Fitzgerald, G. F., Coffey, A. (2004). Evaluation of a Cocktail of Three Bacteriophages for Biocontrol of Escherichia coli O157:H7. Appl. Environ. Microbiol. 70: 3417-3424.

40. Ovcherenko, T.M., A. P. Baturo, G. V. Yalsyk, and N. A. Arefyeva. 1992. Immunobiological properties and therapeutic effectiveness of preparations from Klebsiella bacteriophages. Zh. Mikrobiol. Epidemiol. Immunobiol. 3:30-33.

41. Pavlenishvili, I., and T. Tsertsvadze. 1993. Bacteriophagotherapy and enterosorbtion in treatment of sepsis of newborns caused by gram-negative bacteria. Pren. Neon. Infect. 11:104.

42. Peremitina, L. D., E. A. Berillo, and A. G. Khvoles. 1981. Experience in the therapeutic use of bacteriophage preparations in suppurative surgical infections. Zh. Mikrobiol. Epidemiol. Immunobiol. 9:109-110.

43. Perepanova, T. S., O. S. Darbeeva, G. A. Kotliarova, E. M. Kondrat'eva, L. M. Maiskaia, V. F. Malysheva, F. A. Baiguzina, and N. V. Grishkova. 1995. The efficacy of bacteriophage preparations in treating inflammatory urologic diseases. Urol. Nefrol. 5:14-17.

44. Pokrovskaya, M. P., L. C. Kaganova, M. A. Morosenko, A. G. Bulgakova, and E. E. Skatsenko. 1942. Treatment of wounds with bacteriophages, 2nd ed. State Publishing House ìMedgiz,î, Moscow, USSR.

45. Proskurov, V. A. 1970. Use of staphylococcal bacteriophage for therapeutic and preventive purposes. Zh. Mikrobiol. Epidemiol. Immunobiol. 2:104-107.

46. Rice, T. B. 1930. Use of bacteriophage filtrates in treatment of suppurative conditions: report of 300 cases. Am. J. Med. Sci. 179:345-360.

47. Sakandelidze, V. M., and A. N. Meipariani. 1974. Use of combined phages in suppurative-inflammatory diseases. Zh. Mikrobiol. Epidemiol. Immunobiol. 6:135-136.

48. Sakandelidze, V. M. 1991. The combined use of specific phages and antibiotics in different infectious allergoses. Vrach. Delo 3:60-63.

49. Samsygina, G. A., and E. G. Boni. 1984. Bacteriophages and phage therapy in pediatric practice. Pediatria 4:67-70.

50. Schless, R. A. 1932. Staphylococcus aureus meningitis: treatment with specific bacteriophage. Am. J. Dis. Child. 44:813-822.

51. Shabalova, I. A., N. I. Karpanov, V. N. Krylov, T. O. Sharibjanova, and V. Z. Akhverdijan. 1995. Pseudomonas aeruginosa bacteriophage in treatment of P. aeruginosa infection in cystic fibrosis patients, p. 443. In Proceedings of IX International Cystic Fibrosis Congress. International Cystic Fibrosis Association, Zurich, Switzerland.

52. Slopek, S., I. Durlakowa, B. Weber-Dabrowska, A. Kucharewicz-Krukowska, M. Dabrowski, and R. Bisikiewicz. 1983. Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Arch. Immunol. Ther. Exp. 31:267-291.

53. Slopek, S., I. Durlakowa, B. Weber-Dabrowska, A. Kucharewicz-Krukowska, M. Dabrowski, and R. Bisikiewicz. 1983. Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evaluation of the results. Arch. Immunol. Ther. Exp. 31:293-327.

54. Slopek, S., I. Durlakowa, B. Weber-Dabrowska, M. Dabrowski, and A. Kucharewicz-Krukowska. 1984. Results of bacteriophage treatment of suppurative bacterial infections. III. Detailed evaluation of the results obtained in a further 150 cases. Arch. Immunol. Ther. Exp. 32:317-335.

55. Slopek, S., A. Kucharewicz-Krukowska, B. Weber-Dabrowska, and M. Dabrowski. 1985. Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of the results obtained in 370 cases. Arch. Immunol. Ther. Exp. 33:219-240.

56. Slopek, S., A. Kucharewicz-Krukowska, B. Weber-Dabrowska, and M. Dabrowski. 1985. Results of bacteriophage treatment of suppurative bacterial infections. V. Evaluation of the results obtained in children. Arch. Immunol. Ther. Exp. 33:241-259.

57. Slopek, S., A. Kucharewicz-Krukowska, B. Weber-Dabrowska, and M. Dabrowski. 1985. Results of bacteriophage treatment of suppurative bacterial infections. VI. Analysis of treatment of suppurative staphylococcal infections. Arch. Immunol. Ther. Exp. 33:261-273.

58. Slopek, S., B. Weber-Dabrowska, M. Dabrowski, and A. Kucharewicz-Krukowska. 1987. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch. Immunol. Ther. Exp. 35:569-583.

59. Smith, H. W., and M. B. Huggins. 1982. Successful treatment of experimental Escherichia coli infections in mice using phages: its general superiority over antibiotics. J. Gen. Microbiol. 128:307-318.

60. Smith, H. W., and M. B. Huggins. 1983. Effectiveness of phages in treating experimental E. coli diarrhoea in calves, piglets and lambs. J. Gen. Microbiol. 129:2659-2675.

61. Smith, H. W., and M. B. Huggins. 1987. The control of experimental E. coli diarrhea in calves by means of bacteriophage. J. Gen. Microbiol. 133:1111-1126.

62. Smith, H. W., M. B. Huggins, and K. M. Shaw. 1987. Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. J. Gen. Microbiol. 133:1127-1135.

63. Soothill, J. S., J. C. Lawrence, and G. A. J. Ayliffe. 1988. The efficacy of phages in the prevention of the destruction of pig skin in vitro by Pseudomonas aeruginosa. Med. Sci. Res. 16:1287-1288.

64. Soothill, J. S. 1992. Treatment of experimental infections of mice by bacteriophage. J. Med. Microbiol. 37:258-261.

65. Soothill, J. S. 1994. Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns 20:209-211.

66. Stout, B. F. 1933. Bacteriophage therapy. Texas State J. Med. 29:205-209.

67. Stroj, L., B. Weber-Dabrowska, K. Partyka, M. Mulczyk, and M. Wojcik. 1999. Successful treatment with bacteriophage in purulent cerebrospinal meningitis in a newborn. Neurol. Neurochir. Pol. 3:693-698.

68. Sulakvelidze, A., Alavidze, Z., and Morris, G. Jr. 2001. Bacteriophage Therapy. Antimicrobial Agents and Chemotherapy, March 2001, p. 649-659, Vol. 45, No. 3.

69. Summers, W. C. 1999. Felix d'Herelle and the origins of molecular biology. Yale University Press, New Haven, Conn.

70. Twort, F. W. 1915. An investigation on the nature of ultramicroscopic viruses. Lancet ii:1241.

71. Twort, F. W. 1920. Researches on dysentery. Br. J. Exp. Pathol. 1:237-243.

72. Van Helvoort, T. 1992. Bacteriological and physiological research styles in the early controversy on the nature of the bacteriophage phenomenon. Med. Hist. 3:243-270.

73. Vieu, J. F., F. Guillermet, R. Minck, and P. Nicolle. 1979. Donnees actuelles sur les applications therapeutiques des bacteriophages. Bull. Acad. Natl. Med. 163:61.

74. Weber-Dabrowska, B., M. Dabrowski, and S. Slopek. 1987. Studies on bacteriophage penetration in patients subjected to phage therapy. Arch. Immunol. Ther. Exp. 35:563-568.

75. Weber-Dabrowska, B., M. Zimecki, and M. Mulczyk. 2000. Effective phage therapy is associated with normalization of cytokine production by blood cell cultures. Arch. Immunol. Ther. Exp. 48:31-37.

76. Westwater, C., Kasman, L. M., Schofield, D. A., Werner, P. A., Dolan, J. W., Schmidt, M. G., Norris, J. S. (2003). Use of Genetically Engineered Phage To Deliver Antimicrobial Agents to Bacteria: an Alternative Therapy for Treatment of Bacterial Infections. Antimicrob. Agents Chemother. 47: 1301-1307.

77. Zhukov-Verezhnikov, N., L. Peremitina, E. Berillo, V. Komissarov, V. Bardymov, A. Khvoles, and L. Ugryumov. 1978. A study of the therapeutic effect of bacteriophage agents in a complex treatment of suppurative surgical diseases. Sov. Med. 12:64-66.